Article Versions Notes

Gu SL, Maier T, Moy AP, Dusza S, Faleck DM, Shah NJ, Lacouture ME. IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events. Pharmaceuticals. 2023; 16(11):1548. https://doi.org/10.3390/ph16111548

Gu, Stephanie L., Tara Maier, Andrea P. Moy, Stephen Dusza, David M. Faleck, Neil J. Shah, and Mario E. Lacouture. 2023. "IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events" Pharmaceuticals 16, no. 11: 1548. https://doi.org/10.3390/ph16111548

Gu, S. L., Maier, T., Moy, A. P., Dusza, S., Faleck, D. M., Shah, N. J., & Lacouture, M. E. (2023). IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events. Pharmaceuticals, 16(11), 1548. https://doi.org/10.3390/ph16111548